154 related articles for article (PubMed ID: 36113726)
1. Exosome transportation-mediated immunosuppression relief through cascade amplification for enhanced apoptotic body vaccination.
Zhao G; Liu H; Wang Z; Yang H; Zhao H; Zhang Y; Ge K; Wang X; Luo L; Zhou X; Zhang J; Li Z
Acta Biomater; 2022 Nov; 153():529-539. PubMed ID: 36113726
[TBL] [Abstract][Full Text] [Related]
2. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
3. Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node.
Cheng L; Wang Y; Huang L
Mol Ther; 2017 Jul; 25(7):1665-1675. PubMed ID: 28284981
[TBL] [Abstract][Full Text] [Related]
4. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
5. Transfer of miRNA in tumor-derived exosomes suppresses breast tumor cell invasion and migration by inducing M1 polarization in macrophages.
Moradi-Chaleshtori M; Shojaei S; Mohammadi-Yeganeh S; Hashemi SM
Life Sci; 2021 Oct; 282():119800. PubMed ID: 34245773
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel-loaded M1 macrophage-derived exosomes for a safe and efficient chemoimmunotherapy of breast cancer.
Zhao Y; Zheng Y; Zhu Y; Li H; Zhu H; Liu T
J Nanobiotechnology; 2022 Aug; 20(1):359. PubMed ID: 35918698
[TBL] [Abstract][Full Text] [Related]
7. TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice.
Yildirim M; Yildirim TC; Turay N; Bildik T; Ibibik B; Evcili I; Ersan PG; Tokat UM; Sahin O; Gursel I
Immunol Lett; 2021 Nov; 239():32-41. PubMed ID: 34418488
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer.
Shi X; Sun J; Li H; Lin H; Xie W; Li J; Tan W
Prostate; 2020 Aug; 80(11):811-823. PubMed ID: 32427375
[TBL] [Abstract][Full Text] [Related]
9. T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma.
Li C; Guan N; Liu F
J Neurooncol; 2023 Mar; 162(1):93-108. PubMed ID: 36854924
[TBL] [Abstract][Full Text] [Related]
10. Tumor Microenvironment-Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade-Amplified Immune Response against Tumor Growth, Metastasis and Recurrence.
Gong S; Liang X; Zhang M; Li L; He T; Yuan Y; Li X; Liu F; Yang X; Shen M; Wu Q; Gong C
Small; 2022 Dec; 18(50):e2107061. PubMed ID: 36323618
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy.
Naseri M; Bozorgmehr M; Zöller M; Ranaei Pirmardan E; Madjd Z
Oncoimmunology; 2020 Jun; 9(1):1779991. PubMed ID: 32934883
[TBL] [Abstract][Full Text] [Related]
12. Amplified Cancer Immunotherapy of a Surface-Engineered Antigenic Microparticle Vaccine by Synergistically Modulating Tumor Microenvironment.
Zhao H; Zhao B; Wu L; Xiao H; Ding K; Zheng C; Song Q; Sun L; Wang L; Zhang Z
ACS Nano; 2019 Nov; 13(11):12553-12566. PubMed ID: 31689085
[TBL] [Abstract][Full Text] [Related]
13. Reeducating Tumor-Associated Macrophages Using CpG@Au Nanocomposites to Modulate Immunosuppressive Microenvironment for Improved Radio-Immunotherapy.
Cao Y; Ding S; Zeng L; Miao J; Wang K; Chen G; Li C; Zhou J; Bian XW; Tian G
ACS Appl Mater Interfaces; 2021 Nov; 13(45):53504-53518. PubMed ID: 34704726
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy.
Chang LS; Leng CH; Yeh YC; Wu CC; Chen HW; Huang HM; Liu SJ
Mol Cancer; 2014 Mar; 13():60. PubMed ID: 24642245
[TBL] [Abstract][Full Text] [Related]
15. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
16. Biomineralized hydrogel DC vaccine for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment.
Huo W; Yang X; Wang B; Cao L; Fang Z; Li Z; Liu H; Liang XJ; Zhang J; Jin Y
Biomaterials; 2022 Sep; 288():121722. PubMed ID: 35963815
[TBL] [Abstract][Full Text] [Related]
17. In situ photothermal nano-vaccine based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors.
Huang D; Wu T; Lan S; Liu C; Guo Z; Zhang W
Biomaterials; 2022 Oct; 289():121808. PubMed ID: 36137415
[TBL] [Abstract][Full Text] [Related]
18. Cancer derived exosomes induce macrophages immunosuppressive polarization to promote bladder cancer progression.
Jiang Z; Zhang Y; Zhang Y; Jia Z; Zhang Z; Yang J
Cell Commun Signal; 2021 Sep; 19(1):93. PubMed ID: 34521440
[TBL] [Abstract][Full Text] [Related]
19. Exosome-mediated miR-33 transfer induces M1 polarization in mouse macrophages and exerts antitumor effect in 4T1 breast cancer cell line.
Moradi-Chaleshtori M; Bandehpour M; Heidari N; Mohammadi-Yeganeh S; Mahmoud Hashemi S
Int Immunopharmacol; 2021 Jan; 90():107198. PubMed ID: 33249048
[TBL] [Abstract][Full Text] [Related]
20. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
